Session 1: Extent of Resection and its Role in the Current Molecular Era
Tracks
Hall 1
| Thursday, October 1, 2026 |
| 8:00 AM - 9:30 AM |
Details
Jean-Michel Lemée, Asgeir Jakola
Speakers & Chairs
Dr. Christine Jungk
Consultant
Klinikum Memmingen
Role of extent of resection in Astrocytoma (IDH-mutant)
8:00 AM - 8:10 AM
Asgeir Jakola
Interaction between molecular findings and extent of resection
8:10 AM - 8:20 AM
Federico Pessina
Role of extent of resection in brain metastases
8:20 AM - 8:30 AM
Prof Franz Ricklefs
Full Professor, Attending
University Medical Center Hamburg-Eppendorf
Epigenetic Neural Subclassification Identifies Glioblastoma Patients Benefiting from Supramaximal Resection: A Multicenter Cohort Study
Mr Kirill Mironov
Student
University Of Heidelberg
Residual tumor volumetric cut-offs after primary resection of glioblastoma: Exploring differences between MGMT promoter methylated and unmethylated patients
Dr Francesco Certo
Consultant
University Of Catania
Is FLAIRectomy Feasible in Recurrent Glioblastoma? A Single-Institution Experience in a Series of 56 Patients
Dr. Tommaso Araceli
Resident
University Hospital Regensburg, Department of Neurosurgery
Supramarginal resection improves progression-free and overall survival in patients with infiltrative brain metastases: a prospective cohort study
Mr Jan Kueckelhaus
Resident
Friedrich Alexander University Erlangen-Nürnberg
PREOPERATIVE ASSESSMENT OF PERCEIVED GLIOMA RESECTABILITY BETWEEN INTERNATIONAL EXPERTS
Dr Johannes Kasper
Senior Physician
Chemnitz Hospital
The prognostic effect of extent of resection classified by RANO in elderly patients with newly diagnosed glioblastoma: a single-center analysis
Dr Philipp Karschnia
Neurosurgeon
University Hospital Erlangen
Discrepancies in inter-rater agreement on resectability of recurrent glioblastoma: a complementary post-hoc analysis of the prospective, randomized DIRECTOR trial
Discussion
Discussion
9:25 AM - 9:30 AM
Asgeir Jakola
Chair
Jean-Michel Lemée
Chair
